Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
56.30
+0.40 (0.72%)
Oct 19, 2026, 9:53 AM EDT - Market open
Arrowhead Pharmaceuticals Employees
Arrowhead Pharmaceuticals had 711 employees as of September 30, 2025. The number of employees increased by 102 or 16.75% compared to the previous year. That makes Arrowhead Pharmaceuticals the 17,358th largest employer in the world and 2,408th in the United States.
Employees
711
Change (1Y)
102
Growth (1Y)
16.75%
Revenue / Employee
$941,624
Profits / Employee
-$450,007
Market Cap
7.95B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 711 | 102 | 16.75% |
| Sep 30, 2024 | 609 | 84 | 16.00% |
| Sep 30, 2023 | 525 | 128 | 32.24% |
| Sep 30, 2022 | 397 | 68 | 20.67% |
| Sep 30, 2021 | 329 | 97 | 41.81% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| Ionis Pharmaceuticals | 1,480 |
| Axsome Therapeutics | 1,346 |
| Twist Bioscience | 979 |
| Cytokinetics | 673 |
| TG Therapeutics | 399 |
| Kymera Therapeutics | 273 |
| Praxis Precision Medicines | 168 |
ARWR News
- 4 days ago - Arrowhead assumed with a Buy at UBS - TheFly
- 4 days ago - Arrowhead Pharmaceuticals Transcript: Study update - Transcripts
- 4 days ago - Arrowhead Pharmaceuticals Slides: Study update - Filings
- 4 days ago - Arrowhead Pharmaceuticals Press release: Study update - Filings
- 5 days ago - Arrowhead announces interim results from ongoing Phase 1/2a study of ARO-MAPT - TheFly
- 5 days ago - Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers - Business Wire
- 12 days ago - Arrowhead announces US FDA granted plozasiran entry into STAR program - TheFly
- 12 days ago - Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia - Business Wire